上海市免疫治療創(chuàng)新研究院（以下簡稱“研究院”）經(jīng)上海市人民政府批準(zhǔn)設(shè)立，由上海市人民政府和上海交通大學(xué)共同建設(shè)。研究院面向“健康中國”這一國家戰(zhàn)略,，由國際著名免疫學(xué)家,、中國科學(xué)院院士董晨教授領(lǐng)銜,，依托上海交通大學(xué)醫(yī)學(xué)院及其附屬仁濟(jì)醫(yī)院進(jìn)行系統(tǒng)性建設(shè),，整合上海交通大學(xué)醫(yī)學(xué)院和仁濟(jì)醫(yī)院在免疫學(xué)基礎(chǔ)研究和臨床免疫的學(xué)科優(yōu)勢及豐富的臨床資源優(yōu)勢,，深度融入張江,、臨港國家實(shí)驗(yàn)室整體發(fā)展布局,，以免疫學(xué)相關(guān)基礎(chǔ)和應(yīng)用基礎(chǔ)研究為切入點(diǎn),，聚焦腫瘤免疫治療、慢性炎癥疾病與移植免疫,、傳染性疾病與疫苗三大重點(diǎn)研發(fā)方向和應(yīng)用領(lǐng)域,，努力建設(shè)成為具有全球影響力的免疫創(chuàng)新策源地、免疫學(xué)領(lǐng)域的高端和關(guān)鍵人才的引育基地,、國際一流的免疫學(xué)基礎(chǔ)創(chuàng)新到產(chǎn)業(yè)應(yīng)用的轉(zhuǎn)化基地,。
研究院現(xiàn)有空間位于上海交通大學(xué)醫(yī)學(xué)院重慶南路園區(qū)1號(hào)樓6、7兩層（1000㎡）和仁濟(jì)醫(yī)院東院區(qū)科研樓14樓（1500㎡）,；另有仁濟(jì)醫(yī)院南院區(qū)8000㎡實(shí)用面積的科研空間正在裝修中,，預(yù)計(jì)于2022年投入使用。
上海市免疫治療創(chuàng)新研究院誠邀國內(nèi)外青年英才加盟,，包括相關(guān)高層次人才計(jì)劃申報(bào)者,、青年學(xué)科骨干（PI）、專職科研人員及優(yōu)秀博士后研究人員,。我們將提供優(yōu)厚的薪酬待遇,、良好的成長空間及全面的生活保障。
Shanghai Immune Therapy Institute (SITI), approved by Shanghai Municipal People’s Government, is jointly established and run by Shanghai Jiao Tong University School of Medicine (SJTUSM) and its affiliated Renji Hospital under the leadership of Dr. DONG Chen, world famous immunologist and Academician of the Chinese Academy of Sciences. SITI will gather advantages of both SJTUSM and Renji Hospital in basic and clinical advantages in immunology and integrate itself into the overall development outlook of State key laboratories in the Zhangjiang National Innovation Demonstration Zone and the Lingang free trade area in Pudong New District. Tumor immunotherapy, chronic inflammatory diseases and transplantation immunology, and infectious diseases and vaccines are the three major R&D and application areas for our institute.
SITI will make its share of contribution to the high-quality development of the biomedicine industry in Shanghai and the national strategy of Healthy China. Phased goals for the institute include being built into a full-chain scientific research platform regarding immune-related diseases by 2025. It is also expected to become an R&D center with a group of internationally influential professionals in this field and with global influence.
By 2035, SITI is set to have an internationally leading position in the research fields of new drug targets, new mechanisms, antibody drug development, immunotherapy and other major immune-related diseases. It is expected to become a core element in Shanghai's world-class biomedical industry cluster, which is under construction, as well as in the city's independent innovation efforts.
Join us:
SITI welcomes young talents from both home and abroad to join us on this exciting journey of scientific exploration to improve human health. Posts available include high-level talent program applicants, PI, full-time researchers and post-doc research fellows. We will provide competitive salaries and remuneration, promising career development opportunities and strong support for relocation.
